Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Presentations demonstrate therapeutic potential of Turnstone’s selected tumor-infiltrating lymphocyte therapy in a broad range of solid tumors and support ongoing clinical efforts for its lead program, TIDAL-01

SAN DIEGO--(BUSINESS WIRE)--#AACR2023--Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat solid tumors, today announced that two abstracts have been accepted for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando, Florida, April 14-19, 2023. The presentations include preclinical data for TIDAL-01, Turnstone’s lead tumor-infiltrating lymphocyte therapy candidate based on the selection of tumor-reactive T cells (Selected TILs), which is currently being evaluated in two Phase 1b trials, as well as data showcasing an additional strategy for tumor-reactive T cell selection.

“We look forward to sharing preclinical data at the AACR Annual Meeting which continue to validate the exciting potential of our next-generation Selected TILs across a wide range of solid tumors,” said Stewart Abbot, Ph.D., Chief Scientific Officer, Turnstone Biologics. “These results build upon evidence from our previously published data and further demonstrate the successful expansion and significant enrichment of our TILs using innovative selection strategies for identifying tumor-reactive T cells, and support clinical advancement of TIDAL-01 and our pipeline programs.”

The work reflects Turnstone’s on-going collaboration with the University of Montreal Hospital Research Centre [Centre de recherche du Centre hospitalier de l’Université de Montréal, (CRCHUM)].

Full abstracts are available through the AACR conference website, and details of the poster presentations are as follows:

Title: TIDAL-01: A selected TIL process that enriches for neoantigen-reactive TIL in solid tumors
Session Category: Immunology
Session Title: Adoptive Cell and Natural Killer Cell Therapy
Session Date and Time: April 18, 2023, 9:00 a.m. – 12:30 p.m.
Location: Orange County Convention Center, Poster Section 22
Poster Board Number: 1
Published Abstract Number: 4049

Title: Direct selection of PD1+ CD39+ tumor-infiltrating lymphocytes (TIL) from tumor dissociates enrich for functional tumor-reactive cells
Session Category: Immunology
Session Title: Adoptive Cell and Natural Killer Cell Therapy
Session Date and Time: April 18, 2023, 9:00 a.m. – 12:30 p.m.
Location: Orange County Convention Center, Poster Section 22
Poster Board Number: 4
Published Abstract Number: 4052

About Turnstone Biologics

Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy. Building on the clinical validation in the field, Turnstone’s innovative TIL therapy is based on identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, which have the potential to extend therapeutic benefit and curative outcomes to a broader set of solid tumor indications, beyond where current first-generation TILs have proven effective. The Company’s leading therapy, TIDAL-01, is currently being evaluated in two Phase 1b studies in patients with melanoma, breast cancer, and colorectal cancer. Turnstone has also forged strong partnerships with leading cell therapy researchers and international cancer medical centers, including a landmark strategic alliance with the Moffitt Cancer Center covering research, manufacturing, and clinical development, and a CRADA with the National Cancer Institute to explore unique combinations of Selected TILs with Turnstone’s proprietary viral immunotherapies.

For more information, please visit www.turnstonebio.com, and follow us on LinkedIn.

Ahmed Aneizi
Turnstone Biologics
(347) 897-5988
ahmed.aneizi@turnstonebio.com